Every Form 4 that ELITE PHARMS INC (ELTP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ELTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELTP filings page.
ELITE PHARMACEUTICALS INC (ELTP) director Barry H Dash reported purchasing 30,000 shares of common stock on August 19, 2026, in a purchase described as an open market or private transaction at $0.287 per share.
After this buy, he directly owns 3,265,555 shares of ELTP common stock, and no Rule 10b5-1 plan is reported for this transaction.
Elite Pharmaceuticals executive Douglas Plassche reported an option exercise. On 01/09/2026, the EVP of Operations exercised stock options covering 2,500,000 shares of Elite Pharmaceuticals common stock at an exercise price of $0.03 per share, converting them into 2,500,000 shares of common stock.
The stock options were fully vested and exercisable as of the transaction date. Following this transaction, Plassche directly beneficially owns 6,000,000 shares of Elite Pharmaceuticals common stock and holds no remaining derivative securities from this reported option grant.
Elite Pharmaceuticals (ELTP) filed a Form 4 disclosing that EVP Operations Douglas Plassche sold common stock. On 10/02/2025, he executed a sale (code S) of 800,000 shares at a price of $0.624 per share. Following the transaction, he beneficially owns 3,500,000 shares, held directly.
The filing identifies the reporting person as an officer (EVP Operations) and indicates the ownership form as direct. No derivative securities transactions were reported in Table II.